Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Association between baseline serum glucose, triglycerides and total cholesterol, and prostate cancer risk categories.

Arthur R, Møller H, Garmo H, Holmberg L, Stattin P, Malmstrom H, Lambe M, Hammar N, Walldius G, Robinson D, Jungner I, Hemelrijck MV.

Cancer Med. 2016 Jun;5(6):1307-18. doi: 10.1002/cam4.665. Epub 2016 Feb 29.

2.

Association of serum lipid levels and prostate cancer severity among Hispanic Puerto Rican men.

Salgado-Montilla J, Soto Salgado M, Surillo Trautmann B, Sánchez-Ortiz R, Irizarry-Ramírez M.

Lipids Health Dis. 2015 Sep 17;14:111. doi: 10.1186/s12944-015-0096-0.

3.

Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study.

Rider JR, Sandin F, Andrén O, Wiklund P, Hugosson J, Stattin P.

Eur Urol. 2013 Jan;63(1):88-96. doi: 10.1016/j.eururo.2012.08.001. Epub 2012 Aug 10.

PMID:
22902040
4.

Glucose, lipids and gamma-glutamyl transferase measured before prostate cancer diagnosis and secondly diagnosed primary tumours: a prospective study in the Swedish AMORIS cohort.

Bosco C, Garmo H, Hammar N, Walldius G, Jungner I, Malmström H, Holmberg L, Van Hemelrijck M.

BMC Cancer. 2018 Feb 20;18(1):205. doi: 10.1186/s12885-018-4111-5.

5.

Low levels of apolipoprotein A-I and HDL are associated with risk of prostate cancer in the Swedish AMORIS study.

Van Hemelrijck M, Walldius G, Jungner I, Hammar N, Garmo H, Binda E, Hayday A, Lambe M, Holmberg L.

Cancer Causes Control. 2011 Jul;22(7):1011-9. doi: 10.1007/s10552-011-9774-z. Epub 2011 May 12.

PMID:
21562751
6.

Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial.

Muller RL, Gerber L, Moreira DM, Andriole G, Castro-Santamaria R, Freedland SJ.

Eur Urol. 2012 Nov;62(5):757-64. doi: 10.1016/j.eururo.2012.05.025. Epub 2012 May 18.

PMID:
22658758
7.

Prostate cancer risk in the Swedish AMORIS study: the interplay among triglycerides, total cholesterol, and glucose.

Van Hemelrijck M, Garmo H, Holmberg L, Walldius G, Jungner I, Hammar N, Lambe M.

Cancer. 2011 May 15;117(10):2086-95. doi: 10.1002/cncr.25758. Epub 2010 Nov 29.

8.

Glucose and lipoprotein biomarkers and breast cancer severity using data from the Swedish AMORIS cohort.

Melvin JC, Garmo H, Holmberg L, Hammar N, Walldius G, Jungner I, Lambe M, Van Hemelrijck M.

BMC Cancer. 2017 Apr 4;17(1):246. doi: 10.1186/s12885-017-3232-6.

9.

Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort.

Bhindi B, Locke J, Alibhai SMH, Kulkarni GS, Margel DS, Hamilton RJ, Finelli A, Trachtenberg J, Zlotta AR, Toi A, Hersey KM, Evans A, van der Kwast TH, Fleshner NE.

Eur Urol. 2015 Jan;67(1):64-70. doi: 10.1016/j.eururo.2014.01.040. Epub 2014 Feb 14.

PMID:
24568896
10.

Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study.

Jamnagerwalla J, Howard LE, Allott EH, Vidal AC, Moreira DM, Castro-Santamaria R, Andriole GL, Freeman MR, Freedland SJ.

Prostate Cancer Prostatic Dis. 2018 Jun;21(2):252-259. doi: 10.1038/s41391-017-0030-9. Epub 2017 Dec 27.

11.

Mortality among men with locally advanced prostate cancer managed with noncurative intent: a nationwide study in PCBaSe Sweden.

Akre O, Garmo H, Adolfsson J, Lambe M, Bratt O, Stattin P.

Eur Urol. 2011 Sep;60(3):554-63. doi: 10.1016/j.eururo.2011.05.047. Epub 2011 Jun 1.

PMID:
21664039
12.
13.

A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.

Klein EA, Cooperberg MR, Magi-Galluzzi C, Simko JP, Falzarano SM, Maddala T, Chan JM, Li J, Cowan JE, Tsiatis AC, Cherbavaz DB, Pelham RJ, Tenggara-Hunter I, Baehner FL, Knezevic D, Febbo PG, Shak S, Kattan MW, Lee M, Carroll PR.

Eur Urol. 2014 Sep;66(3):550-60. doi: 10.1016/j.eururo.2014.05.004. Epub 2014 May 16.

14.

Differences in the aggressiveness of prostate cancer among Korean, Caucasian, and African American men: A retrospective cohort study of radical prostatectomy.

Jeong IG, Dajani D, Verghese M, Hwang J, Cho YM, Hong JH, Kim CS, Ahn H, Ro JY.

Urol Oncol. 2016 Jan;34(1):3.e9-14. doi: 10.1016/j.urolonc.2015.08.004. Epub 2015 Sep 4.

PMID:
26345648
15.

Gleason inflation 1998-2011: a registry study of 97,168 men.

Danneman D, Drevin L, Robinson D, Stattin P, Egevad L.

BJU Int. 2015 Feb;115(2):248-55. doi: 10.1111/bju.12671.

16.

Serum glucose, triglycerides, and cholesterol in relation to prostate cancer death in the Swedish AMORIS study.

Arthur R, Møller H, Garmo H, Häggström C, Holmberg L, Stattin P, Malmström H, Lambe M, Hammar N, Walldius G, Robinson D, Jungner I, Van Hemelrijck M.

Cancer Causes Control. 2018 Nov 12. doi: 10.1007/s10552-018-1093-1. [Epub ahead of print]

PMID:
30421156
17.

Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study.

Stattin P, Vickers AJ, Sjoberg DD, Johansson R, Granfors T, Johansson M, Pettersson K, Scardino PT, Hallmans G, Lilja H.

Eur Urol. 2015 Aug;68(2):207-13. doi: 10.1016/j.eururo.2015.01.009. Epub 2015 Feb 11.

18.

Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer.

Buzzoni C, Auvinen A, Roobol MJ, Carlsson S, Moss SM, Puliti D, de Koning HJ, Bangma CH, Denis LJ, Kwiatkowski M, Lujan M, Nelen V, Paez A, Randazzo M, Rebillard X, Tammela TL, Villers A, Hugosson J, Schröder FH, Zappa M.

Eur Urol. 2015 Nov;68(5):885-90. doi: 10.1016/j.eururo.2015.02.042. Epub 2015 Mar 16.

19.

The risk of prostate cancer for men on aspirin, statin or antidiabetic medications.

Nordström T, Clements M, Karlsson R, Adolfsson J, Grönberg H.

Eur J Cancer. 2015 Apr;51(6):725-33. doi: 10.1016/j.ejca.2015.02.003. Epub 2015 Feb 23.

PMID:
25727881
20.

Association between type 2 diabetes, curative treatment and survival in men with intermediate- and high-risk localized prostate cancer.

Crawley D, Garmo H, Rudman S, Stattin P, Zethelius B, Holmberg L, Adolfsson J, Van Hemelrijck M.

BJU Int. 2018 Feb;121(2):209-216. doi: 10.1111/bju.13880. Epub 2017 May 17.

PMID:
28418195

Supplemental Content

Support Center